Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001846444-25-000017·Acumen Pharmaceuticals, Inc.
Schedule 13G ownership disclosure
Acumen Pharmaceuticals, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 00509G209
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Sands Capital Alternatives, LLC
Shares: 3,417,075.00 · Class: 5.6%
- Sands Capital Ventures Discovery Fund III, L.P.
Shares: 1,124,729.00 · Class: 1.9%
- Sands Capital Global Venture Fund II, L.P.
Shares: 1,146,173.00 · Class: 1.9%
- Sands Capital Life Sciences Pulse Fund, LLC
Shares: 1,146,173.00 · Class: 1.9%
- SANDS FRANK M.
Shares: 3,417,075.00 · Class: 5.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001846444-25-000017
- Form type
- SCHEDULE 13G/A
- Filer
- Acumen Pharmaceuticals, Inc.
- CIK
- CIK 1576885
- Filed
- Aug 13, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership